Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Rhea-AI Summary

Cyclo Therapeutics to present at 8th Annual Dawson James Conference

Live webcast presentation on Thursday, October 12^th at 12:00 PM ET

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8^th Annual Dawson James Conference being held in Jupiter, FL on Thursday, October 12, 2023 at 12:00 PM ET.

In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol^® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

About Dawson James
Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology, Clean tech, and Consumer sectors. We are a full-service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. By investing the time required to completely understand your business, we can provide an appropriate capital transaction structure and strategy including direct investment through our independent fund. Our team will assist in crafting your vision and shaping your message for the capital markets. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland, and New Jersey. www.dawsonjames.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231005589716/en/

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Source: Cyclo Therapeutics, Inc.

FAQ

When and where is the presentation?

The presentation will be held on Thursday, October 12th at 12:00 PM ET in Jupiter, FL.

Who will be presenting?

N. Scott Fine, Chief Executive Officer, and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics.

Will there be in-person meetings with investors?

Yes, management will be available for one-on-one meetings with qualified members of the investor community.

Where can I watch the presentation online?

A live webcast will be available on the Events page of the Investors section of the company's website.

Will there be a replay of the webcast?

Yes, a webcast replay will be available on the company's website for 90 days.